Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes

• DOI: 10.18502/jovr.v18i2.13182
• Publication Date: 2023-05-01T12:01:00Z
• Authors: Siamak Moradian; Masoud Soheilian; Mahsan Asadi; Abdolreza Baghi; Hamid Safi; Seyed-Hossein Abtahi
• Keywords: Diabetic macular edema; Aflibercept

To evaluate the effects of intravitreal ziv-aflibercept injections (IVZ) on subfoveal choroidal thickness (SCT) as well central macular (CMT) and best corrected visual acuity (BCVA) changes in eyes with center-involved diabetic edema (CI-DME).Fifty-seven 36 patients CI-DME were included this prospective interventional case series. Structural optical coherence tomography (OCT) enhanced depth imaging OCT performed at baseline followed by three monthly 1.25 mg IVZ injections. Changes SCT, CMT, BCVA each follow-up session assessed. The association between SCT its final anatomical outcomes also assessed.CMT baseline, first, second, third month sessions 396 ± 119, 344 115, 305 89, 296 101 μm, respectively (P-value < 0.001). months one, two, 236 47, 245 56, 254 54, 241 54 > 0.99). Corresponding figures for 0.58 0.29, 0.47 0.31, 0.4 0.24, 0.37 0.23 LogMAR, There was a statistically significant positive correlation CMT following However, there no correlations (VA) injections.IVZ improved profiles CI-DME. had effect SCT. Baseline outcomes.